We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.49%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$312M
AUM Growth
+$302M
Cap. Flow
+$306M
Cap. Flow %
98.25%
Top 10 Hldgs %
48.33%
Holding
84
New
6
Increased
59
Reduced
1
Closed
18

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$30.2M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$25.2M
3
INCY icon
Incyte
INCY
+$20M
4
ALKS icon
Alkermes
ALKS
+$15.4M
5
GILD icon
Gilead Sciences
GILD
+$12.6M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.77M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$121K
3
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$107K
4
FOLD
Amicus Therapeutics
FOLD
+$94.6K
5
IMVT icon
Immunovant
IMVT
+$60K

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
26
Guardant Health
GH
$22.6B
$4M 1.28%
74,500
+71,495
+2,379% +$3.67M
AMGN icon
27
Amgen
AMGN
$236B
$3.66M 1.17%
16,246
+6,331
+64% +$1.53M
RVNC
28
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.24M 1.04%
+120,000
New +$2.43M
NBIX icon
29
Neurocrine Biosciences
NBIX
$15.8B
$3.19M 1.02%
30,000
+6,992
+30% +$709K
UTHR icon
30
United Therapeutics
UTHR
$22.6B
$3.14M 1.01%
15,000
+10,287
+218% +$2.3M
KRYS icon
31
Krystal Biotech
KRYS
$10.6B
$3.13M 1%
45,000
+42,045
+1,423% +$3.04M
VTRS icon
32
Viatris
VTRS
$19.4B
$3.1M 0.99%
+364,000
New +$3.58M
ASND icon
33
Ascendis Pharma A/S
ASND
$16.4B
$3.04M 0.97%
29,400
+26,667
+976% +$2.53M
CRBU icon
34
Caribou Biosciences
CRBU
$178M
$2.72M 0.87%
257,892
+256,514
+18,615% +$2.39M
FATE icon
35
Fate Therapeutics
FATE
$304M
$2.71M 0.87%
121,000
+117,083
+2,989% +$3.38M
ZLAB icon
36
Zai Lab
ZLAB
$3.01B
$2.69M 0.86%
78,958
+76,222
+2,786% +$3.26M
NVCR icon
37
NovoCure
NVCR
$2.09B
$2.43M 0.78%
32,000
+29,776
+1,339% +$2.32M
NVAX icon
38
Novavax
NVAX
$1.49B
$2.41M 0.77%
132,500
+125,686
+1,845% +$5.45M
JAZZ icon
39
Jazz Pharmaceuticals
JAZZ
$16.3B
$2.29M 0.73%
17,200
+14,517
+541% +$2.21M
CRSP icon
40
CRISPR Therapeutics
CRSP
$5.74B
$2.23M 0.72%
34,200
+32,122
+1,546% +$2.33M
ACET icon
41
Adicet Bio
ACET
$84.3M
$2.19M 0.7%
+9,669
New +$2.45M
ONC
42
BeOne Medicines Ltd
ONC
$42.1B
$2.12M 0.68%
15,700
+13,158
+518% +$2.26M
NBP
43
NovaBridge Biosciences American Depositary Shares
NBP
$219M
$2.02M 0.65%
507,239
+501,007
+8,039% +$3.8M
IDYA icon
44
IDEAYA Biosciences
IDYA
$4.03B
$1.63M 0.52%
109,000
+107,499
+7,162% +$1.4M
FULC icon
45
Fulcrum Therapeutics
FULC
$294M
$1.56M 0.5%
193,741
+192,792
+20,315% +$1.38M
LEGN icon
46
Legend Biotech
LEGN
$3.99B
$1.55M 0.5%
38,000
+37,752
+15,223% +$1.77M
CNCE
47
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.34M 0.43%
200,800
+198,190
+7,593% +$1.2M
NTLA icon
48
Intellia Therapeutics
NTLA
$1.84B
$1.34M 0.43%
24,000
+22,758
+1,832% +$1.41M
DNLI icon
49
Denali Therapeutics
DNLI
$3.94B
$1.17M 0.37%
38,000
+36,882
+3,299% +$1.2M
BEAM icon
50
Beam Therapeutics
BEAM
$3.15B
$1.12M 0.36%
23,500
+22,590
+2,482% +$1.29M
1
2
3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2022 Portfolio in Review

As of Q3 2022, International Biotechnology Trust held 84 positions worth $312M, up 3,153% from $9.59M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

International Biotechnology Trust deployed $306M of net new capital in Q3 2022, opening 6 new positions and adding to 59 existing holdings. Its largest new stake was Viatris: 364,000 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $1.77M trimmed.

  • International Biotechnology Trust's largest Q3 2022 buy was Viatris: 364,000 shares worth $3.1M.
  • International Biotechnology Trust added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $30.2M increase.
  • International Biotechnology Trust's biggest Q3 2022 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.77M.
  • International Biotechnology Trust fully exited ChemoCentryx, Inc. in Q3 2022, selling an estimated $121K.
  • International Biotechnology Trust's ten largest holdings make up 48% of its $312M portfolio in Q3 2022.
  • International Biotechnology Trust opened 6 new positions and closed 18 in Q3 2022.
  • International Biotechnology Trust's portfolio value rose 3,153% quarter-over-quarter to $312M.

Based on International Biotechnology Trust's 13F filing for Q3 2022, filed 8 Nov 2022.